Protara is evaluating TARA-002 in Phase 2 trials for NMIBC patients with carcinoma in situ who are unresponsive or naïve to BCG treatment, and in pediatric patients with lymphatic malformations. The company is also developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support.
Cyborg Score Rationale
Analysts in good agreement that stock price will rise by 300.9%, and recent Phase 2 data demonstrates 68% complete response rates with Breakthrough Therapy designation. Currently unprofitable and not forecast to become profitable over the next 3 years, typical for clinical-stage companies.
Top Insights
Protara highlighted strong Phase 2 data for TARA-002 as of February 24, 2026
80% of patients that completed treatment achieved clinical success with one or two doses of TARA-002 in pediatric lymphatic malformations
Breakthrough Therapy and Fast Track designations accelerate regulatory pathway to market
TARA's weekly volatility (14%) is higher than 75% of US stocks, reflecting clinical-stage risk premium
Named Competitors
Cell Therapy Platforms — Competing CAR-T and cell therapy approaches
Checkpoint Inhibitors — Systemic immunotherapy alternatives for BCG-unresponsive bladder cancer
Other Rare Disease Therapies — Competing approaches to rare disease treatment
Recent Developments
(February 2026) TARA-002 achieves 68% complete response rate at six months in BCG-unresponsive NMIBC patients